000046926 001__ 46926
000046926 005__ 20210121114543.0
000046926 0247_ $$2doi$$a10.1007/s12094-015-1316-9
000046926 0248_ $$2sideral$$a92223
000046926 037__ $$aART-2015-92223
000046926 041__ $$aeng
000046926 100__ $$aAntolín-Novoa, S.
000046926 245__ $$aAdjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice
000046926 260__ $$c2015
000046926 5060_ $$aAccess copy available to the general public$$fUnrestricted
000046926 5203_ $$aPurpose: Trastuzumab has proven to improve the prognosis of HER2-positive breast cancer, but the information available about its administration for small tumors is still limited. Therefore, we assessed the use of adjuvant regimens with trastuzumab for the treatment of small HER2-positive breast cancer in routine clinical practice. Methods: This observational study was conducted in patients with HER2-positive breast adenocarcinoma =1.5 cm who received trastuzumab-based adjuvant treatment in clinical practice. Clinical/histopathological data were retrieved from patients’ medical charts. Results: A total of 101 evaluable patients were enrolled (median age range], 56.7 49.0–64.8] years//ECOG 0, 98.0 %//ductal carcinoma, 88.1 %//lymph nodes N0, 79.2 %). Only five (5.0 %) patients received neoadjuvant treatment, while all patients underwent tumor surgery. Adjuvant trastuzumab was administered at a mean (±SD) dose of 5.9 ± 1.5 mg/kg/cycle, and mostly in a three-weekly schedule (89 89.0 %] patients). The most frequent adjuvant therapy used with trastuzumab was chemotherapy (87 86.1 %] patients), followed by radiotherapy (63 62.4 %] patients) and hormone therapy (52 51.5 %] patients). Chemotherapy regimens mainly included doxorubicin, cyclophosphamide and paclitaxel/docetaxel (n = 30), docetaxel and cyclophosphamide (n = 15), docetaxel and carboplatin (n = 13). Hormone therapy mainly included letrozole (n = 17) and tamoxifen (n = 17). Nine (8.9 %) patients reported trastuzumab-related adverse events//only one allergic reaction reached grade 3 toxicity. Conclusion: This study shows that trastuzumab-based adjuvant treatment of small HER2-positive breast cancer is mostly based on chemotherapy—mainly paclitaxel/docetaxel. Adjuvant administration of trastuzumab for small HER2-positive breast cancer seems to be similar to that used for larger tumors.
000046926 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000046926 590__ $$a2.075$$b2015
000046926 591__ $$aONCOLOGY$$b153 / 213 = 0.718$$c2015$$dQ3$$eT3
000046926 592__ $$a0.865$$b2015
000046926 593__ $$aMedicine (miscellaneous)$$c2015$$dQ2
000046926 593__ $$aOncology$$c2015$$dQ2
000046926 593__ $$aCancer Research$$c2015$$dQ3
000046926 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000046926 700__ $$aBlanco-Campanario, E.
000046926 700__ $$0(orcid)0000-0002-9159-4988$$aAntón, A.$$uUniversidad de Zaragoza
000046926 700__ $$aGallegos-Sancho, M.
000046926 700__ $$aPérez-Carrión, R.
000046926 700__ $$aPeláez, I.
000046926 700__ $$aGalán-Brotons, A.
000046926 700__ $$ade la Cruz-Merino, L.
000046926 700__ $$aMurías-Rosales, A.
000046926 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000046926 773__ $$g17, 11 (2015), 862-869$$pClin. transl. oncol.$$tClinical and Translational Oncology$$x1699-048X
000046926 8564_ $$s545002$$uhttps://zaguan.unizar.es/record/46926/files/texto_completo.pdf$$yVersión publicada
000046926 8564_ $$s98026$$uhttps://zaguan.unizar.es/record/46926/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000046926 909CO $$ooai:zaguan.unizar.es:46926$$particulos$$pdriver
000046926 951__ $$a2021-01-21-11:17:36
000046926 980__ $$aARTICLE